Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf108 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hideto Kameda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Spondylitis, Ankylosing, Axial Spondyloarthritis, Antirheumatic Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objectives
To evaluate the long-term safety and effectiveness of ixekizumab for axial spondyloarthritis in the real-world setting in Japan.
Methods
This single-arm, multicentre, observational study was conducted from 26 May 2020 to 10 March 2023 on adult patients with axial spondyloarthritis who were administered ixekizumab under daily clinical practice in Japan. Baseline patient characteristics were summarized. Adverse events, adverse drug reactions, physician-rated overall improvement, and patient-reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were assessed for 96 weeks after ixekizumab initiation.
Results
Of the 39 enrolled patients, 29 consented to publication and were included in these analyses (n = 21 ankylosing spondylitis; n = 8 non-radiographic axial spondyloarthritis). Sixteen patients (55.2%) were male, with a median (range) age of 52.0 (32.0–76.0) years. Fourteen (48.3%) and 4 (13.8%) patients experienced adverse events and adverse drug reactions, respectively, most commonly infections and administration site reactions. No serious adverse events or adverse drug reactions were reported. Across 96 weeks, physicians rated ≥75.0% patients as showing improvement. BASDAI scores showed trends consistent with improvement.
Conclusions
These findings are consistent with ixekizumab clinical trial data from other countries, showing the long-term safety and effectiveness of ixekizumab in patients with axial spondyloarthritis under routine clinical care in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
- Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
- Graduate School of Health Science, Morinomiya University of Medical Sciences, Osaka, Japan.
Förderung
- Eli Lilly and Company
Zitieren
APA
Kameda, H., Dong, J., Yamamoto, C., Konomi, A., Nishikawa, Y., & Tomita, T. (2025). Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf108
Vancouver
Kameda H, Dong J, Yamamoto C, Konomi A, Nishikawa Y, Tomita T. Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf108
BibTeX
@article{Kameda2025,
author = {Kameda, Hideto and Dong, Jiayi and Yamamoto, Chie and Konomi, Ayako and Nishikawa, Yumiko and Tomita, Tetsuya},
title = {Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf108}
}
EUVIMED